Prostate screening with the PSA blood test is medicine’s most debated checkup, because it saves some lives while overdiagnosing many slow cancers. Current US guidance recommends an individualized discussion for men aged fifty five to sixty nine, earlier for those with family history, and routine screening is generally discouraged past seventy. Enter age, PSA and family history for the matching category.
Your visual report appears here
Fill in the form and press Calculate. You will get your number, an interpretation chip, and a personalized chart pack drawn instantly in your browser.
- Risk spectrum with your position marked
- Reference ranges from the original publication
- Shareable link, nothing stored
Scientific references
No cancer screening divides experts like the PSA test. Large trials show it prevents a small number of prostate cancer deaths, while the same trials show it diagnoses many cancers that would never have caused harm, exposing men to biopsies and treatments with real risks of incontinence and impotence. Modern guidance threads that needle with shared decision making.
The Age Bands
Under fifty five, routine screening is not recommended unless risk factors apply, notably a father or brother with the disease or African ancestry, both of which roughly double risk. From fifty five to sixty nine sits the discussion window, where the task force says the choice belongs to an informed man and his doctor weighing personal values. Past seventy, harms outweigh benefits for most, since competing illnesses dominate and treatment side effects weigh heavier.
Reading PSA Sensibly
PSA is not a cancer test but a prostate activity test. Infection, recent ejaculation, cycling and benign enlargement all raise it. Traditional worry begins above four, though age adjusted cutoffs and velocity, the speed of rise, read smarter. A stable level of two point five in a sixty year old typically means annual watching, while a jump from one to three in a year earns a urology conversation regardless of the absolute value.
What a Positive Leads To
Modern pathways no longer rush to biopsy. MRI first, then targeted sampling only of suspicious areas, and active surveillance for low grade findings have transformed the tradeoff, cutting overdiagnosis harm substantially while keeping the survival benefit.
Screening decisions are preference sensitive by definition. This guide frames the categories, the conversation supplies the answer.